JP2002504505A - ブトルファノール持続放出性製剤 - Google Patents

ブトルファノール持続放出性製剤

Info

Publication number
JP2002504505A
JP2002504505A JP2000533099A JP2000533099A JP2002504505A JP 2002504505 A JP2002504505 A JP 2002504505A JP 2000533099 A JP2000533099 A JP 2000533099A JP 2000533099 A JP2000533099 A JP 2000533099A JP 2002504505 A JP2002504505 A JP 2002504505A
Authority
JP
Japan
Prior art keywords
butorphanol
composition
oil
composition according
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000533099A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002504505A5 (https=
Inventor
チヤン，フン−チー
リー，ルクチウ
テン，ユーチユイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of JP2002504505A publication Critical patent/JP2002504505A/ja
Publication of JP2002504505A5 publication Critical patent/JP2002504505A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2000533099A 1998-02-25 1999-02-25 ブトルファノール持続放出性製剤 Pending JP2002504505A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3021798A 1998-02-25 1998-02-25
US09/030,217 1998-02-25
PCT/US1999/004113 WO1999043300A1 (en) 1998-02-25 1999-02-25 Butorphanol sustained release formulations

Publications (2)

Publication Number Publication Date
JP2002504505A true JP2002504505A (ja) 2002-02-12
JP2002504505A5 JP2002504505A5 (https=) 2006-04-20

Family

ID=21853121

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000533099A Pending JP2002504505A (ja) 1998-02-25 1999-02-25 ブトルファノール持続放出性製剤

Country Status (8)

Country Link
US (1) US6197344B1 (https=)
EP (1) EP1056443B1 (https=)
JP (1) JP2002504505A (https=)
AT (1) ATE265846T1 (https=)
AU (1) AU753278B2 (https=)
CA (1) CA2321924A1 (https=)
DE (1) DE69917000T2 (https=)
WO (1) WO1999043300A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6680067B2 (en) * 2001-11-26 2004-01-20 Oliver Yoa-Pu Hu Controlled-release pharmaceutical preparation containing nalbuphine and a process for preparing the same
JP2005526079A (ja) * 2002-03-15 2005-09-02 サイプレス バイオサイエンス， インコーポレイテッド 内蔵痛症候群を処置するためのｎｅおよび５−ｈｔ再取り込み阻害剤
EP1545468A4 (en) * 2002-09-20 2007-06-20 Alpharma Inc SUSTAINED RELEASE OPIOID PREPARATIONS AND METHODS OF USE
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
EP1592453A1 (en) * 2003-01-28 2005-11-09 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
RU2254852C1 (ru) * 2004-01-23 2005-06-27 Ефим Давыдович Нежинский Раствор для инъекций, обладающий выраженным анальгетическим действием, и способ его получения
US20080227805A1 (en) * 2007-02-28 2008-09-18 Abbott Laboratories Sustained release parenteral formulations of buprenorphine
EP2632441A4 (en) * 2010-10-29 2015-04-01 Relmada Therapeutics Inc COMPOSITIONS OF (-) - 17- (CYCLOBUTYLMETHYL-) MORPHINAN-3,14-DIOL
AR101476A1 (es) 2014-08-07 2016-12-21 Acerta Pharma Bv Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)
US10183018B2 (en) 2015-05-28 2019-01-22 Lumosa Therapeutics Co., Ltd. Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
EP3302477B1 (en) 2015-05-28 2024-02-07 Lumosa Therapeutics Co., Ltd. Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
US11234974B2 (en) 2015-05-28 2022-02-01 Lumosa Therapeutics Co., Ltd. Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
CN111904928A (zh) * 2019-05-07 2020-11-10 江苏恒瑞医药股份有限公司 一种包含布托啡诺的可注射的药物组合物及其制备方法
CN116818928B (zh) * 2023-04-28 2024-04-19 杭州沐源生物医药科技有限公司 一种酒石酸布托啡诺注射液中杂质的分离检测方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51144721A (en) * 1975-05-26 1976-12-13 Ciba Geigy Ag Long lasting effective carcytonine composition and its production
JPH01110621A (ja) * 1987-07-24 1989-04-27 Vestar Res Inc オピオイド鎮痛剤のリポソーム運搬−放出系
JPH05507694A (ja) * 1990-06-14 1993-11-04 アプリカシオネス　ファルマシューティカス，ソシエダド　アノニマ　デ　カピタル　バリアブレ 注射可能な医薬組成物
WO1997044039A1 (en) * 1996-05-20 1997-11-27 Janssen Pharmaceutica N.V. Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE788478A (fr) 1971-09-08 1973-03-06 Bristol Myers Co Procede de preparation de composes analgesiques
US4338324A (en) * 1981-03-17 1982-07-06 Mcneilab, Inc. Analgesic potentiation
US4322427A (en) 1981-04-16 1982-03-30 Bristol-Myers Company Analgetic compositions and methods of use
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
GB9226905D0 (en) * 1992-12-24 1993-02-17 Wellcome Found Pharmaceutical preparation
JP2596255Y2 (ja) 1993-03-23 1999-06-07 ナカミチ株式会社 ディスク再生装置
WO1996024330A1 (en) 1995-02-10 1996-08-15 Medtronic, Inc. Method and device for administering analgesics

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51144721A (en) * 1975-05-26 1976-12-13 Ciba Geigy Ag Long lasting effective carcytonine composition and its production
JPH01110621A (ja) * 1987-07-24 1989-04-27 Vestar Res Inc オピオイド鎮痛剤のリポソーム運搬−放出系
JPH05507694A (ja) * 1990-06-14 1993-11-04 アプリカシオネス　ファルマシューティカス，ソシエダド　アノニマ　デ　カピタル　バリアブレ 注射可能な医薬組成物
WO1997044039A1 (en) * 1996-05-20 1997-11-27 Janssen Pharmaceutica N.V. Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6009046581, 新・薬剤学総論（改訂第３版）, 1987, 第２６１頁, 株式会社 南江堂 *

Also Published As

Publication number Publication date
ATE265846T1 (de) 2004-05-15
EP1056443B1 (en) 2004-05-06
AU3311299A (en) 1999-09-15
DE69917000T2 (de) 2005-04-21
EP1056443A1 (en) 2000-12-06
DE69917000D1 (de) 2004-06-09
US6197344B1 (en) 2001-03-06
AU753278B2 (en) 2002-10-10
WO1999043300A1 (en) 1999-09-02
CA2321924A1 (en) 1999-09-02

Similar Documents

Publication Publication Date Title
JP2002504505A (ja) ブトルファノール持続放出性製剤
JP2518605B2 (ja) 水不溶性薬剤を含む微小滴
US20060078618A1 (en) Lipid particles and suspensions and uses thereof
JPH0834745A (ja) アルファトコフェロールをベースにした小胞体
KR20020066778A (ko) 체내 난흡수 물질의 흡수촉진용 조성물과 제형 및 그의제조방법
JP2003505403A (ja) 経鼻抗痙攣組成物及び調節方法
JP2003500454A (ja) 実質的にオイルフリーのシクロスポリン組成物
JP2002531518A (ja) インスリン含有医薬組成物
JPH10203964A (ja) 難吸収性薬剤の経口生物学的利用能を改善する新しい調剤
CZ302649B6 (cs) Farmaceutická formulace zahrnující cyklosporin a její použití
JPH10330287A (ja) 多価不飽和脂肪酸からなる消化管吸収促進剤およびそれを含有する薬剤
WO1998005300A2 (en) Delivery system for pharmaceutical agents encapsulated with oils
JP2004520398A (ja) 経口生物学的利用能が改善されたパクリタキセルの化学療法マイクロエマルジョン組成物
US8455508B2 (en) Sustained release parenteral formulations of buprenorphine
EP4199904B1 (en) Nano lipid carrier system for improving permeation of active ingredients
AU2007351338B2 (en) Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use
CA2562495C (fr) Utilisation de dipalmitostearate de glycerol pour ameliorer la biodisponibilite de principes actifs proteiques en formulations injectables sous-cutanees ou intramusculaires
JP3074732B2 (ja) 脂肪乳剤
Chang et al. Parenteral sustained-release dosage forms of butorphanol for dogs
JP2634047B2 (ja) アルファトコフェロールをベースとした小胞体
Bojrup et al. Bioavailability of cyclosporine in rats after intragastric administration: a comparative study of the L2-phase and two other lipid-based vehicles
US7968124B2 (en) Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use
JPWO1991007964A1 (ja) 脂肪乳剤
Ogiso et al. Enhancement effect of lauric acid on the rectal absorption of propranolol from suppository in rats
JP4694776B2 (ja) 微小粒子組成物又はリポソーム製剤

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20050208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090908

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091201

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091208

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100608